AAM names 2023 board of directors

The Association for Accessible Medicines has elected its 2023 board of directors and officers.

Christine Baeder, senior vice president and chief operating officer for U.S. generics, Teva Pharmaceuticals USA is the 2023 AAM chair of the board.

AAM also named Keren Haruvi, president, Sandoz U.S., head of North America, vice chair of the board and Jeff Burd, president, Ajanta Pharma as treasurer.

[Read more: AAM reacts to Avalere study on generic drug costs]

The 2023 AAM board of directors includes:

• Accord Healthcare, Jeff Hampton, president
• Ajanta Pharma USA, Jeff Burd, president
• American Regent, Paul Diolosa, president and CEO
• Amneal, Maryll Toufanian, senior vice president of regulatory strategy & policy
• Amphastar, Dan Dischner, vice president, corporate communications
• Apotex, Peter Hardwick, president and CEO
• Aurobindo, Paul McMahon, president, commercial operations
• Biocon, Matt Erick, chief commercial officer – advanced markets
• B. Braun Medical, Rob Albert, senior vice president and chief marketing officer
• Cipla, Arunesh Verma, CEO
• Dr. Reddy's, Vanessa Brill, vice president legal and compliance, Americas
• Fresenius Kabi, John Ducker, president and CEO
• Glenmark, Sanjeev Krishan, president North America
• Hikma, Brian Hoffmann, president U.S. generics division
• Jubilant Cadista, Kevin Fortier, chief commercial officer
• Lupin, Bob Hoffman, chief commercial officer
• Meitheal, Tom Shea, CEO
• Sagent, Peter Kaemmerer, CEO
• Sandoz, Keren Haruvi, president, Sandoz U.S., head of North America
• Sun, Abhay Gandhi, CEO, North America
• Teva, Christine Baeder, senior vice president and chief operating officer for U.S. generics
• Torrent, Sanjay Gupta, president and CEO
• Zydus, Crystal Fisher, vice president, general counsel and compliance officer

[Read more: Challenges continue, but generics companies see a bright future with biosimilars]